Gilead Still Sees Strong Demand Despite Weaker HIV Product Sales
Setback For Magrolimab In Hematology
The drug maker said channel mix was behind a year-over-year decline in HIV product sales, while competition and capacity constraints weighed on cell therapy sales growth.
